Iveric Bio Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Iveric Bio Inc (ISEE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Iveric Bio Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Iveric Bio Inc | - | - | - | No |
| Competitors combined (166) | ||||
| High-Confidence Competitors (3) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ISEE Stock Performance relative to its Competitors
ISEE Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 2 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 3 | Erasca Inc | 282.9% | Outperformed |
| 4 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 5 | Climb Bio Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Iveric Bio Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Iveric Bio Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Iveric Bio Inc | 5,476.63 | - |
| Beone Medicines Ltd | 550,872.13 | 6,128.24 |
| Novartis Ag | 278,724.35 | 56,674.00 |
| Astrazeneca Plc | 252,216.14 | 58,739.00 |
| Vertex Pharmaceuticals Inc | 133,421.11 | 12,587.20 |
| Bristol myers Squibb Company | 127,795.20 | 49,186.00 |
| SUBTOTAL | 1,627,960.96 | 213,409.08 |
Sign in to see all competitors of Iveric Bio Inc .
Sources: Iveric Bio Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Iveric Bio Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Iveric Bio Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ngm Biopharmaceuticals Inc | Named by the company | 85% |
| Apellis Pharmaceuticals Inc | Named by the company | 85% |
| Disc Medicine Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Iveric Bio Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Iveric Bio Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
| Ligand Pharmaceuticals Incorporated | Development and Licensing of Biopharmaceutical Assets 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Iveric Bio Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Iveric Bio Inc | 5,477 | - | -2,122,895 |
| Beone Medicines Ltd | 550,872 | 510,686 | 54,642 |
| Novartis Ag | 278,724 | 752,973 | 185,566 |
| Astrazeneca Plc | 252,216 | 706,847 | 123,141 |
| Vertex Pharmaceuticals Inc | 133,421 | 31,079,506 | 10,877,037 |
| Bristol myers Squibb Company | 127,795 | 1,513,415 | 285,354 |
| PEERS TOTAL | 1,622,484 | 895,747 | 138,762 |
Iveric Bio Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Beone Medicines Ltd | United States 51.69 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Bristol myers Squibb Company | United States 67.79 % |
| United Therapeutics Corporation | UNITED STATES 95.23 % |
| Xoma Royalty Corporation | CH 54.36 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Iveric Bio Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.9x | - |
| EV / EBITDA | - | 17.1x | - |
| P/B | 8.6x | 4.5x | +4.1x |
| Return on Equity | -57.00 % | industry aggregate | -71.03 % |
| Return on Invested Capital | -27.19 % | -2.85 % (avg) | -24.34 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Iveric Bio Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2015 | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | - | -1.16 % | - | - | - | - | - |
| Operating Margin | -239.84 % | -384.14 % | - | - | - | - | - |
| Return on Invested Capital | -23.16 % | -67.76 % | 85.62 % | -29.01 % | -23.69 % | -25.64 % | -25.44 % |
| P/E | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Iveric Bio Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 71.0 points below the industry aggregate.
Opportunities
- A meaningful share of tracked competitors (50.60 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-64.7% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Iveric Bio Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Iveric Bio Inc | 9.82 | 15.24 | 0.15 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Iveric Bio Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Iveric Bio Inc | Q1 2023 | - | - |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| PEERS TOTAL | +10.0 % | +44.5 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Iveric Bio Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Iveric Bio Inc | Q1 2023 | - | +100.9 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
Iveric Bio Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Iveric Bio Inc | - | - | - |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Iveric Bio Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Iveric Bio Inc | - | - |
| Beone Medicines Ltd | 831.68 | 89.89 |
| Novartis Ag | 19.93 | 4.92 |
| Astrazeneca Plc | 24.67 | 4.29 |
| Vertex Pharmaceuticals Inc | 30.48 | 10.60 |
| Bristol myers Squibb Company | 13.74 | 2.60 |
| PEERS AVERAGE | 49.58 | 7.63 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.